CORRECTION

CrossMark

Correction to: Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis

Tomoko Fujii[1,2] , Riki Ganeko[3], Yuki Kataoka[4], Toshi A. Furukawa[5], Robin Featherstone[6], Kent Doi[7], Jean-Louis Vincent[8], Daniela Pasero[9], René Robert[10], Claudio Ronco[11] and Sean M. Bagshaw[12]*

Correction to: Intensive Care Med
https://doi.org/10.1007/s00134-017-5004-9
Owing to an oversight by the authors, Fig. 2 in this article was not the version intended for publication. The correct Fig. 2, reproduced here, features footnote symbols and Fig. 2b includes three studies as described in the main text.

*Correspondence: bagshaw@ualberta.ca
[12] Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, 2-124 Clinical Sciences Building, 8440-112 ST NW, Edmonton, Canada T6G 2B7
Full author information is available at the end of the article

Springer

a

Study or Subgroup	PMX–HP Events	Total	Standard therapy Events	Total	Weight	Risk Ratio M–H, Random, 95% CI	Year
1.1.1 Abdominal sepsis							
Vincent 2005	5	17	5	18	6.6%	1.06 [0.37, 3.02]	2005
Cruz 2009	11	34	16	30	17.5%	0.61 [0.34, 1.09]	2009
Payen 2015	33	119	22	113	24.1%	1.42 [0.89, 2.29]	2015
Subtotal (95% CI)		170		161	48.3%	0.98 [0.54, 1.78]	
Total events	49		43				
Heterogeneity: Tau² = 0.16; Chi² = 4.96, df = 2 (P = 0.08); I² = 60%							
Test for overall effect: Z = 0.08 (P = 0.94)							
1.1.2 Sepsis with various etiologies including abdominal							
Cantaluppi 2008	2	8	3	8	3.4%	0.67 [0.15, 2.98]	2008
EUPHRATES 2017 ✳	84	224	78	226	48.4%	1.09 [0.85, 1.39]	2017
Subtotal (95% CI)		232		234	51.7%	1.07 [0.84, 1.37]	
Total events	86		81				
Heterogeneity: Tau² = 0.00; Chi² = 0.40, df = 1 (P = 0.53); I² = 0%							
Test for overall effect: Z = 0.56 (P = 0.57)							
Total (95% CI)		402		395	100.0%	1.03 [0.78, 1.36]	
Total events	135		124				
Heterogeneity: Tau² = 0.03; Chi² = 5.35, df = 4 (P = 0.25); I² = 25%							
Test for overall effect: Z = 0.20 (P = 0.84)							
Test for subgroup differences: Chi² = 0.08, df = 1 (P = 0.78), I² = 0%							

Risk Ratio M–H, Random, 95% CI — 0.1 0.2 0.5 1 2 5 10 — Favours PMX–HP / Favours Standard therapy

b

Study or Subgroup	PMX–HP Events	Total	Standard therapy Events	Total	Weight	Risk Ratio M–H, Random, 95% CI	Year
Vincent 2005	1	17	0	18	13.8%	3.17 [0.14, 72.80]	2005
Payen 2015	6	119	3	113	73.0%	1.90 [0.49, 7.41]	2015
EUPHRATES 2017 ✳	1	224	0	226	13.3%	3.03 [0.12, 73.90]	2017
Total (95% CI)		360		357	100.0%	2.17 [0.68, 6.94]	
Total events	8		3				
Heterogeneity: Tau² = 0.00; Chi² = 0.13, df = 2 (P = 0.93); I² = 0%							
Test for overall effect: Z = 1.30 (P = 0.19)							

Risk Ratio M–H, Random, 95% CI — 0.01 0.1 1 10 100 — Favours PMX–HP / Favours Standard therapy

c

Study or Subgroup	PMX–HP Mean	SD	Total	Standard therapy Mean	SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI	Year
Vincent 2005 ✳	8.5	4.4	17	9	4.4	18	15.8%	−0.11 [−0.77, 0.55]	2005
Cantaluppi 2008 ✳	5.4	3.4	8	10.4	5.9	8	9.1%	−0.98 [−2.04, 0.07]	2008
Cruz 2009 †	−3.4	2.9	34	−0.1	4.3	30	19.6%	−0.90 [−1.42, −0.38]	2009
Payen 2015	8.3	3.6	119	7.5	3.5	113	26.9%	0.22 [−0.03, 0.48]	2015
EUPHRATES 2017 ✳†	−2	3.7	224	−1.6	3.3	226	28.6%	−0.11 [−0.30, 0.07]	2017
Total (95% CI)			402			395	100.0%	−0.26 [−0.64, 0.12]	
Heterogeneity: Tau² = 0.12; Chi² = 17.94, df = 4 (P = 0.001); I² = 78%									
Test for overall effect: Z = 1.32 (P = 0.19)									

Std. Mean Difference IV, Random, 95% CI — −4 −2 0 2 4 — Favours PMX–HP / Favours Standard therapy

Fig. 2 Forest plot of comparison: PMX-HP versus standard therapy. *PMX-HP* polymyxin B-immobilized hemoperfusion. †Reported change data. *Data provided by the study author

Author details

[1] Department of Epidemiology and Preventive Medicine, Kyoto University Graduate School of Medicine, Yoshida Hon-machi, Sakyo-ku, Kyoto, Japan. [2] Japan Society for the Promotion of Science, 5-3-1 Kojimachi, Chiyoda-ku, Tokyo, Japan. [3] Department of Surgery, Kyoto University Hospital, 54 Kawaharacho, Syogoin, Sakyo-ku, Kyoto, Japan. [4] Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Higashi-Naniwa-Cho 2-17-77, Amagasaki, Hyogo, Japan. [5] Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine, Yoshida Konoe-cho, Sakyo-Ku, Kyoto, Japan. [6] Department of Pediatrics, Alberta Research Center for Health Evidence (ARCHE), University of Alberta, 11405-87 Avenue Edmonton, Alberta, Canada. [7] Department of Emergency and Critical Care Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan. [8] Department of Intensive Care, Erasme University Hospital, Unversité Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium. [9] Department of Anesthesia and Intensive Care Medicine, San Giovanni Battista Hospital, University of Turin, Via Giuseppe Verdi, 8, 10124 Turin, Italy. [10] Service de Réanimation Médicale, CHU-Poitiers, University of Poitiers, 86000 Poitiers, France. [11] Department of Nephrology Dialysis and Transplantation, International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Viale Rodolfi 37, 36100 Vicenza, Italy. [12] Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, 2-124 Clinical Sciences Building, 8440-112 ST NW, Edmonton, Canada T6G 2B7.